Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.41 |
| ▸ | DRD4 | P21917 | 8/20 | 0.41 |
| ▸ | DRD3 | P35462 | 8/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721467 | 0.81 | GRIN1 (0.42) | DRD2DRD4DRD3CHRM1CHRM2 | |
| SCHEMBL14419535 | 0.80 | — | — | |
| SCHEMBL1764224 | 0.80 | DRD2 (0.60) | DRD2DRD4DRD3CHRM1CHRM2 | |
| SCHEMBL20257167 | 0.79 | PBRM1 (0.43) | DRD2DRD4DRD3CHRM1CHRM2 | |
| SCHEMBL4240939 | 0.79 | CHRM1 (0.53) | DRD2DRD4DRD3CHRM1CHRM2 | |
| SCHEMBL5384961 | 0.78 | DRD2 (0.59) | DRD2DRD4DRD3CHRM1CHRM2 | |
| SCHEMBL5654457 | 0.77 | — | — | |
| SCHEMBL4230639 | 0.76 | CHRM1 (0.52) | DRD2DRD4DRD3CHRM1GRIN1 | |
| SCHEMBL5389753 | 0.75 | DRD2 (0.62) | DRD2DRD4DRD3CHRM1CHRM2 | |
| SCHEMBL6721735 | 0.75 | MTNR1A (0.46) | CHRM1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213535-A1 | Process for the manufacture of aripiprazole by using purified carbostyril compounds such as 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones | CHEMAGIS LTD. (IL) | 2007-09-13 | — | — | US | disclosed |
| US-20070213535-A1 | Process for the manufacture of aripiprazole by using purified carbostyril compounds such as 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones | CHEMAGIS LTD. (IL) | 2007-09-13 | — | — | US | disclosed |
| US-20070213535-A1 | Process for the manufacture of aripiprazole by using purified carbostyril compounds such as 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones | CHEMAGIS LTD. (IL) | 2007-09-13 | — | — | US | disclosed |
| US-20060079689-A1 | Processes for preparing and purifying carbostyril compounds such as aripiprazole and 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones | CHEMAGIS LTD. (IL) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213535-A1 | Process for the manufacture of aripiprazole by using purified carbostyril compounds such as 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones | CYP3A4, CYP2J2, CYP2A7 | DRD2 239/4885DRD4 143/4885DRD3 817/4885 |
| US-20060079689-A1 | Processes for preparing and purifying carbostyril compounds such as aripiprazole and 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones | HRH2, CYP2J2, HTR7 | DRD2 370/4885DRD4 532/4885DRD3 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.